IRIS
ABBADESSA, GIANMARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.909
AS - Asia 1.893
NA - Nord America 1.600
SA - Sud America 316
AF - Africa 36
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.757
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.036
US - Stati Uniti d'America 1.549
SG - Singapore 601
CN - Cina 459
VN - Vietnam 272
IE - Irlanda 271
HK - Hong Kong 262
BR - Brasile 248
IT - Italia 208
DE - Germania 130
KR - Corea 105
GB - Regno Unito 85
IN - India 77
JP - Giappone 43
AR - Argentina 28
FI - Finlandia 24
CA - Canada 22
MX - Messico 20
FR - Francia 19
SE - Svezia 19
UA - Ucraina 19
EC - Ecuador 15
AT - Austria 14
NL - Olanda 14
GR - Grecia 13
PL - Polonia 13
ID - Indonesia 10
IQ - Iraq 10
MA - Marocco 10
TR - Turchia 10
CZ - Repubblica Ceca 9
BE - Belgio 8
BD - Bangladesh 6
CH - Svizzera 6
CO - Colombia 6
EG - Egitto 6
IL - Israele 6
VE - Venezuela 6
PK - Pakistan 5
CL - Cile 4
ES - Italia 4
TN - Tunisia 4
UZ - Uzbekistan 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
JO - Giordania 3
KE - Kenya 3
PE - Perù 3
PY - Paraguay 3
RS - Serbia 3
UY - Uruguay 3
BH - Bahrain 2
ET - Etiopia 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LU - Lussemburgo 2
MY - Malesia 2
NG - Nigeria 2
PA - Panama 2
PT - Portogallo 2
SA - Arabia Saudita 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CG - Congo 1
DK - Danimarca 1
EU - Europa 1
HN - Honduras 1
HT - Haiti 1
HU - Ungheria 1
IR - Iran 1
JM - Giamaica 1
LT - Lituania 1
MD - Moldavia 1
MT - Malta 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
RO - Romania 1
SN - Senegal 1
TT - Trinidad e Tobago 1
Totale 7.757
Salva come PNG Salva come JPEG
Città #
Moscow 1.096
San Jose 322
Dublin 271
Singapore 259
Hong Kong 256
Santa Clara 214
Hefei 134
Dallas 119
Ashburn 115
Ho Chi Minh City 105
Seoul 101
Chandler 70
Hanoi 57
Munich 57
Beijing 53
Bengaluru 49
Naples 37
New York 37
Roxbury 34
Princeton 33
Los Angeles 31
Cambridge 26
The Dalles 25
São Paulo 23
Memphis 21
Bremen 19
Da Nang 19
Jacksonville 19
Caserta 15
Orem 15
Medford 14
Milan 14
Ann Arbor 13
Boardman 12
Helsinki 12
San Francisco 11
Warsaw 11
Chicago 10
Frankfurt am Main 10
Rome 10
Stockholm 10
Tokyo 10
Atlanta 9
Falkenstein 9
Mexico City 9
Brussels 8
Des Moines 8
Rio de Janeiro 8
Toronto 8
Boston 7
Brasília 7
Haiphong 7
Hải Dương 7
Amsterdam 6
Baghdad 6
Buffalo 6
Grafing 6
Guangzhou 6
Lappeenranta 6
London 6
Montreal 6
Pasadena 6
Turku 6
Bari 5
Biên Hòa 5
Brno 5
Buenos Aires 5
Bắc Ninh 5
Chennai 5
Curitiba 5
Hillsboro 5
Nuremberg 5
Phoenix 5
Porto Alegre 5
Redwood City 5
Thái Bình 5
Vienna 5
Viterbo 5
Wilmington 5
Zurich 5
Ankara 4
Aversa 4
Brooklyn 4
Bến Tre 4
Can Tho 4
Changsha 4
Guarulhos 4
Houston 4
Huế 4
Lviv 4
Nanjing 4
Newark 4
Ninh Bình 4
Norwalk 4
Raleigh 4
Rockville 4
Tashkent 4
Athens 3
Belgrade 3
Casablanca 3
Totale 4.078
Salva come PNG Salva come JPEG
Nome #
Atypical Progressive Multifocal Leukoencephalopathy in a Kidney Transplant Recipient With Improving Symptoms After Immunocompetence Recovery 172
Telemedicine application to headache: a critical review 169
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 165
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence 155
Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells 149
Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series 147
Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis 146
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study 144
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study 140
Digital Health in Diabetes Care: A Narrative Review from Monitoring to the Management of Systemic and Neurologic Complications 139
Cd19 cell count at baseline predicts b cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab 139
Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic 139
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 138
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 136
e-Health and multiple sclerosis: An update 136
Association between relapses, stress, and depression in people with multiple sclerosis during the COVID-19 pandemic 136
Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study 135
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab 135
Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review 131
Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail 129
Disability assessment using Google Maps 129
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis 128
Signs and symptoms of COVID-19 in patients with multiple sclerosis 127
Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis 123
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis 121
Right phrenic nerve palsy following transcatheter radiofrequency current atrial fibrillation ablation: Case report 119
Social Media and Multiple Sclerosis in the Posttruth Age. 118
Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study 118
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 117
MRI and steroid-responsive encephalopathy associated with autoimmune thyroiditis: first report of conus medullaris involvement and literature review of the known neuroimaging profiles 117
Viral pericarditis following ocrelizumab in a multiple sclerosis patient 115
Pain, quality of life, and religiosity in people with multiple sclerosis 114
Digital work engagement among Italian neurologists 114
The Use of Social Media and Digital Devices Among Italian Neurologists 113
Readability Analysis of Online Headache and Migraine Information 113
Behind the scenes: exploring neurological journal editors' work habits, decisions, and potential sources of conflict of interest 111
How to manage with telemedicine people with neuromuscular diseases? 110
Hemostatic factors in the pathogenesis of neuroinflammation in multiple sclerosis 110
Public engagement and neurology: An update 109
Digital therapeutics in neurology 109
Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online. 108
Source of medical information and behavioral seeking patterns in patients affected with Friedreich’s ataxia and their caregivers: a survey study 108
Identifying definite patterns of unmet needs in patients with multiple sclerosis using unsupervised machine learning 105
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 104
Editorial: Bridging the gap between basic neurosciences and clinical neuroimmunology 103
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study 102
Heidenhain variant of Creutzefeldt-Jackob disease in a patient carrying the V210I mutation with asymmetric MRI abnormalities 102
Progressive multifocal leukoencephalopathy presenting with bilateral myoclonus: a case report 101
Understanding and managing the impact of the Covid-19 pandemic and lockdown on patients with multiple sclerosis 100
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 99
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 97
Hemostasis Components as Therapeutic Targets in Autoimmune Demyelination 96
Paraneoplastic syndrome or immune-related adverse event? A case of rhomboencephalitis in a patient treated with Pembrolizumab 94
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 + T-Cell Proliferation in Patients With Multiple Sclerosis 91
Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective study 89
Emotional facial palsy: an unusual and rarely explored neurological sign 88
First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis 87
Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab 86
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop) 85
Glaucoma as a Tauopathy—Is It the Missing Piece in the Glaucoma Puzzle? 82
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 81
Mapping Molecular Pathways of Multiple Sclerosis: A Gene Prioritization and Network Analysis of White Matter Pathology Transcriptomics 74
Modulation of NCX1 expression in monocytes associates with multiple sclerosis progression 73
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 72
Targeting shared pathways in tauopathies and age-related macular degeneration: implications for novel therapies 72
Sexual Dysfunction in People with Multiple Sclerosis: The Role of Disease Severity, Illness Perception, and Depression 71
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study 70
Reply to Wostyn, P. Targeting the Cerebrospinal Fluid Compartment in Glaucoma: Still the Dark Side of the Moon? Comment on “Passaro et al. Glaucoma as a Tauopathy—Is It the Missing Piece in the Glaucoma Puzzle? J. Clin. Med. 2023, 12, 6900” 70
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 70
Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis 58
ANTI-CD20 AGENTS RESHAPE THE PHENOTYPE AND FUNCTIONS OF CYTOTOXIC LYMPHOCYTES AND SELECTIVELY MITIGATE EBV-SPECIFIC CD8+ T CELL REACTIVITY IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 14
Serum miRNAs as biomarkers in Neurofibromatosis 1: New promising findings. 4
Totale 7.871
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.193
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.193
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022240 2 15 4 5 60 15 2 3 17 6 23 88
2022/2023416 63 12 9 11 35 18 2 11 222 6 11 16
2023/2024297 16 11 22 13 79 39 13 5 7 4 11 77
2024/20251.150 2 12 10 75 180 114 145 98 198 98 128 90
2025/20265.595 220 382 387 228 486 2.798 330 287 204 118 109 46
2026/20273 3 0 0 0 0 0 0 0 0 0 0 0
Totale 7.871